Metrnl in diabetes and its complications: divergent evidence and translational prospects

BACKGROUND: Meteorin-like protein (Metrnl) is a novel secreted protein produced by multiple tissues, which is involved in metabolic regulation, immune homeostasis, and tissue repair. In recent years, research on the role of Metrnl in diabetes has advanced significantly. However, substantial controversies persist regarding its expression dynamics, protective roles, and underlying molecular mechanisms in diabetes and its complications. MAIN BODY: This review synthesizes current evidence to systematically analyze the complex roles of Metrnl in diabetes. Preclinical studies have demonstrated that Metrnl primarily improves insulin resistance, protects pancreatic β-cells, and mitigates diabetes related damage to kidney, heart, and skin through multiple pathways, including the KIT receptor, AMPK and Wnt/β-catenin signaling pathways.In contrast, clinical data exhibit significant heterogeneity. Reports on circulating Metrnl levels in patients with type 2 diabetes are highly inconsistent, with findings of decreased, increased, or no significant changes. Such discrepancies are largely attributed to methodological inconsistencies and clinical confounders. Similar inconsistencies are observed in studies on gestational diabetes. Importantly, Metrnl also displays markedly different or even opposing expression patterns across various diabetic complications, highlighting its tissue-specific regulatory characteristics. CONCLUSIONS: In summary, Metrnl is a pleiotropic molecule involved in the pathophysiological processes of diabetes and its complications, and it holds potential as a candidate biomarker or therapeutic target. However, its clinical translation faces key challenges, including insufficient standardization of detection methods, unclear characterization of receptor systems, and undefined pharmacological properties. Therefore, although Metrnl shows promise in preclinical models, its clinical utility requires rigorous validation, and its roles should be interpreted cautiously based on the current body of evidence.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-05-16
DOI
https://doi.org/10.1186/s12967-026-08253-4
Primary Topic
Diabetes and associated disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metrnl in diabetes and its complications: divergent evidence and translational prospects

Biying Meng, Qingyun Tang, Ling Yue, Yongqiang Zhou et al.
Journal of Translational Medicine
Diabetes and associated disorders
article

Metrnl in diabetes and its complications: divergent evidence and translational prospects

Biying Meng, Qingyun Tang, Ling Yue, Yongqiang Zhou, Jiayang Tang, Xiaoliang Yang, Shengwei Zhang, Kang Hu, Yuyang Liu, Guiyu Liu
article en

Abstract

BACKGROUND: Meteorin-like protein (Metrnl) is a novel secreted protein produced by multiple tissues, which is involved in metabolic regulation, immune homeostasis, and tissue repair. In recent years, research on the role of Metrnl in diabetes has advanced significantly. However, substantial controversies persist regarding its expression dynamics, protective roles, and underlying molecular mechanisms in diabetes and its complications. MAIN BODY: This review synthesizes current evidence to systematically analyze the complex roles of Metrnl in diabetes. Preclinical studies have demonstrated that Metrnl primarily improves insulin resistance, protects pancreatic β-cells, and mitigates diabetes related damage to kidney, heart, and skin through multiple pathways, including the KIT receptor, AMPK and Wnt/β-catenin signaling pathways.In contrast, clinical data exhibit significant heterogeneity. Reports on circulating Metrnl levels in patients with type 2 diabetes are highly inconsistent, with findings of decreased, increased, or no significant changes. Such discrepancies are largely attributed to methodological inconsistencies and clinical confounders. Similar inconsistencies are observed in studies on gestational diabetes. Importantly, Metrnl also displays markedly different or even opposing expression patterns across various diabetic complications, highlighting its tissue-specific regulatory characteristics. CONCLUSIONS: In summary, Metrnl is a pleiotropic molecule involved in the pathophysiological processes of diabetes and its complications, and it holds potential as a candidate biomarker or therapeutic target. However, its clinical translation faces key challenges, including insufficient standardization of detection methods, unclear characterization of receptor systems, and undefined pharmacological properties. Therefore, although Metrnl shows promise in preclinical models, its clinical utility requires rigorous validation, and its roles should be interpreted cautiously based on the current body of evidence.

Journal of Translational Medicine
Central Hospital of Wuhan (CN), Baoji City Central Hospital (CN), Wuhan General Hospital of Guangzhou (CN), Pingjin Hospital (CN), Southern Medical University (CN)
National Natural Science Foundation of China
Openalex Percentile: Top 5%
Diabetes and associated disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.